Respiratory syncytial virus: promising progress against a leading cause of pneumonia

Affiliations

¹ University of Washington Clinical Trials Center, University of Washington, Seattle, WA 98115, USA. Electronic address: messageforamy@gmail.com.
² The Bill & Melinda Gates Foundation, Seattle, WA, USA.

Amy Sarah Ginsburg et al. Lancet Glob Health. 2021 Dec.

. 2021 Dec;9(12):e1644-e1645.

doi: 10.1016/S2214-109X(21)00455-1. Epub 2021 Nov 11.

¹ University of Washington Clinical Trials Center, University of Washington, Seattle, WA 98115, USA. Electronic address: messageforamy@gmail.com.
² The Bill & Melinda Gates Foundation, Seattle, WA, USA.

No abstract available

Conflict of interest statement

We declare no competing interests.

1. Ananworanich J, Heaton PM. Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities. Vaccines (Basel) 2021;9:961. - PMC - PubMed
1. Zar HJ, Nduru P, Stadler JAM, et al. Early-life respiratory syncytial virus lower respiratory tract infection in a South African birth cohort: epidemiology and effect on lung health. Lancet Glob Health. 2020;8:e1316–e1325. - PMC - PubMed
1. Srikantiah P, Vora P, Klugman KP. Assessing the full burden of respiratory syncytial virus in young infants in low- and middle-income countries: the importance of community mortality studies. Clin Infect Dis. 2021;73(suppl 3):S177–S179. - PMC - PubMed
1. Shi T, Arnott A, Semogas I, et al. The etiological role of common respiratory viruses in acute respiratory infections in older adults: a systematic review and meta-analysis. J Infect Dis. 2020;222(suppl 7):S563–S569. - PMC - PubMed
1. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–434. - PubMed